Updated survey finds some improvements, but little overall progress since a 2006 survey
Based on a survey of 151 leading pharma companies, Health Industry Insights (Framingham, MA) estimates that 4.4% of industry revenue, or $11 billion, is lost each year through channel and distribution inefficiencies—“equivalent to total revenue for a top 20 pharma simply disappearing each year,” as Eric Newmark, research manager, puts it.
The leakpoints are: chargeback discrepancies, rebate errors, return discrepancies, and concealed shortages (short deliveries). On average, manufacturers overpay managed care rebates by 5.5% and Medicaid rebates by 4.5%. For some companies, these overpayments slip into double-digit range. A typical chargeback scenario: a chargeback (coming from a wholesaler) is flagged for errors and is resubmitted, but only about half of the resubmissions are successfully resolved. Ultimately, the manufacturer and wholesaler choose to split the discrepancy 50:50, resulting in a revenue writeoff for the manufacturer.
In 2006, when IDC Health Insights first performed this survey, fee-for-service agreements with wholesalers were just coming into force; one element of these agreements is generation of EDI data such as 867 or 852 forms. Those data were supposed to make reconciliation of chargebacks easier to handle, but according to Newmark, companies are “often dumbfounded by 867 data due to its enormous volume and the related challenge of configuring it to suit several differing needs across the company.”
Newmark says that corporate CFOs are loosening the pursestrings to acquire IT systems from companies like Model N, I-Many or SAP customizations to manage the data reconciliation, but he wonders why IT vendors aren’t offering to scrub the data themselves or—more to the point—“why wholesalers themselves have not begun offering enhanced data services to make [EDI] data more useful.”
The report, "Revenue Leakage--Pharma's $11-Billion Problem," H1220793, is available for purchase at www.healthindustryinsights.com.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.